MACROMOLECULAR CDP-CHOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Abstract: CDP-choline derivatives with macromolecules contai­ ning carboxy groups, such as polyacrylates, polymethacry­ lates, polyglutamates, polyaspartates and polymaleates, or copolymers of acrylic acid and methacrylic acid with me­ thyl acrylate, methyl methacrylate or acrylamide. The polymeric derivatives of the invention gradual­ ly release CDP-choline, due to the action of enzymes pre­ sent in the organism, thus exerting also a protective effect on the CDP-choline molecule.

Description: The present invention relates to macromolecular CDP-choline derivatives obtained by covalent binding on macromolecular matrices having carboxy groups, processes for the preparation thereof and pharmaceutical composi­ tions containing them. CDP-choline represents the "active" form of choline and it is a key intermediate in the choline phospholipid biosynthesis (Kennedy E.P. in "Novel Biochemical Pharmaco­ logical and Clinical Aspects of CDP-choline", Zappia V. et al., eds. Elsevier N.Y., 3, 1985). CDP-choline is on its turn biosynthesized from P-choline and CTP by means of the choline-phosphate-cyti­ dinetransferase enzyme, isolated from the microsomial fraction. The formation of CDP-choline represents the slowest step, thus limiting the whole phospholipid methabolic pathway (Vance D.E. et al., TIBS, 4 , 145, 1979): the cel­ lular concentrations of said metabolite play therefore a critical role in the regulation of the phospholipid bio­ synthesis. As a consequence of its biochemical roles, the main pharmacological use and prescription of CDP-choline lays in a series of impairments of the Central Nervous System, wherein the structural and functional integrity of the phospholipidic membranes is critical. The pharmacological activity of the molecule has been shown under different clinical conditions such as cerebral apoplexy, different kinds of cerebrovasculopa­ thies, Parkinson's disease, cranial traumathology and consequences thereof (in "Novel Biochemical, Pharmacologi­ cal and Clinical Aspects of CDP-choline", Zappia et al., eds. Elsevier N.Y., 285, 1985). The biochemical background underlying such a kind of pharmacology envisaging the use of a molecule deriving from the cytoplasmatic biosynthesis as a drug, is based on the hypothesis that administration of remarkable amounts of said precursor of phospholipids contributes to the re-synthesis and to the repair of the damaged cerebral membranes (Alberghina et al., J. Neuroscience Res., 6 , 421, 1981; Alberghina et al., J. Neuroscience Res., 6 , 719, 1981; Trovarelli G. et al., Neurochem. Res. 6 , 821, 1981). It has been moreover shown that a series of complex biochemical effects of regulatory type, not directly due to the biosynthesis of choline lipids, play an important role in the definition of the therapeutic properties of CDP-choline (Martinet M. et al., Biochem. Pharmacol. 3O , 53, 1981; Shibuya M. et al., J. Pharmacol., 31 , 47, 1981; Faryna De Raveglia I et al., Neurochem. Res. 7 , 37, 1982; Algate D.R. et al., Arzneimittel Forshung Drug. Res., 33 , (II), 1O22, 1983; Braso M.A. e al., Arzneimittel Forshung Drug. Res., 33 , (II), 1O43, 1983). Pharmacodynamics study at molecular level, carried out using (5-³H; Met-¹⁴C)CDP-choline on different experi­ mental models such as isolated and perfused rat liver, the rat (De Rosa M. et al., in "Novel Biochemical, Pharmacolo­ gical and Clinical Aspects of CDP-choline", Zappia et al., eds. Elsevier N.Y., 139, 1985) and cultured cerebral cells (Vecchini A. et al., Neurochem. Res. 8 , 333, 1983), show that the molecule is actively metabolized. The choline and cytosine components of the drug are found in the lecithine fraction and in the nucleic acids, respectively. The pharmacodynamic experimentation, carried out on the doubly labelled molecule, shows that the administra­ tions by the intravenous and oral routes are generally comparable as far as the drug bioavailability and the amount of the excretory phenomena of the structural label­ led components are concerned, whereas significant diffe­ rences are noticed in the evolution of the pharmacodynamic pattern and in the nature of the labelled molecular species. CDP-choline is mainly administered by parenteral route but recently, also in consideration of deeper know­ ledges acquired on the pharmacodynamics of the molecule, the drug's administration by the oral route attracts con­ siderable interest. Particularly, the possibility of devising therapeu­ tic indications in fields such as that of aging, makes up-to-date slow-release, oral administration forms, which are more suited for prolonged treatments, granting a uni­ form and continuous availability of the active principle. The CDP-choline derivatives object of the present invention fulfil said requisites. The used functionalization strategy is based on the binding of CDP-choline to macromolecular matrices by means of biodegradable covalent bonds, i.e. so as to be cleaved by the enzymes and by the chemico-physical conditions existing in the organism, providing a gradual release of the active principle, which is metabolized. A series of analogues has been synthesized in order to better analyze the structure-function ratio underlying the slow-release mechanism and the structure protection of the active principle, characterizing this class of CDP-­ choline derivatives. The insertion of the drug into a macromolecular matrix modifies in fact in a remarkable manner the structural identity of the active principle, which is not recognized by the degradative enzymes. In the case of oral formulations, the polymer con­ taining CDP-choline acts at the gastro-enteric apparatus level as a reservoir, wherein the molecular structure of the active principle is preserved and from which the CDP-­ choline release takes place gradually. The drug release, by cleavage of the covalent bonds binding CDP-choline to the polymeric matrix, is due to the enzymes and to the chemico-physical characteristics of the gastro-enteric medium. Once released the drug, the macromolecule acting as a carrier, if not biodegradable, is excreted by the faecal route, being not absorbed at the gastro-enteric level because of its high molecular weight. For the parenteral formulations the molecular me­ chanism of the active principle release is similar to that above described for the oral forms. In this case, the characteristics of the carrier polymeric matrix must be so as to allow the elimination by the urinary route or due to its biodegradability or since its molecular weight allows the elimination thereof in the urine through the glomeru­ lar barrier. The functionalization strategy of CDP-choline according to the invention is extremely interesting not only with respect to the previously mentioned pharmacolo­ gical mechanisms, but also for the easiness of the drug optimization as a function of the chemical nature of the polymer, of its molecular weight, of its cross-linking degree and of the number of covalent bonds with the active principle. The high versatility of the macromolecularizat­ ion process of CDP-choline is original and constitutes one of the characterizing element of the derivatives object of the present invention. The functional groups present on CDP-choline, which may be used for the formation of covalent bonds with the macromolecular structure, are the NH₂ group in 4 on the aromatic nucleus and the OH groups in 2' and 3' on the ribose. The need of obtaining easily biodegradable bonds limit the synthetic possibilities to the formation of the ester and amide bonds, using polymeric matrices having carboxy groups. Examples of said polymeric matrices inclu­ de, for instance, polymers such polyacrylic, polymethacry­ lic, polymaleic acids, polyamino acids (polyglutamates, polyaspartates) optionally copolymerized with polyacryla­ tes, polymethaacrylates and polyacrylamides. A number of synthetic strategies may be followed for the preparation of macromolecular CDP-choline derivatives; some alternati­ ve possibilities for the various steps characterising the synthetic scheme are listed hereinafter, without any limi­ ting scope. a) Macromolecularization : it can be performed either bind­ ing CDP-choline to a preformed polymeric matrix or by polymerization of CDP-choline derivatives acylated with polymerizable carboxy acids in conditions not degrading the active principle. b) Activation of the carboxy moiety : the carboxy moiety in order to give rise to the formation of ester- or amide-type bonds with CDP-choline, asks for a previous activation, for instance as an anhydride, chloride or imidazolide. The activation reaction as chloride or imidazolide is carried out in an anhydrous medium, using the conventional halogenating reagents for the chlorides and carbonyldiimidazole for the imidazolides. The reaction yields are quantitative and the solution of the activated derivative may be directly used to acylate CDP-choline. c) Reaction medium.: the acylation reaction must be prefe­ rably carried out in a non-aqueous medium to obtain high yields. Since CDP-choline, for its ionic character, is inso­ luble even in very polar solvents such as dimethylfor­ mamide, it is necessary to use CDP-choline salts with highly lipophilic counter-ions, such as the tetrahexyl­ ammonium ion. Thanks to said expedient, the acylation reaction of the CDP-choline tetrahexylammonium salt may be carried out in homogeneous phase, for instance in anhydrous dime­ thylformamide, by simply adding the activated derivati­ ve of the acid dissolved in the same solvent. d) Stoichiometry of the acylation reaction: the acylating reagent is generally used in a stoichiometric excess with respect to CDP-choline. In the case of acylation of the active principle with activated derivatives of polymerizable acids such as acrylic or methacrylic acids, up to 9 equivalents of acid per mole of CDP-cho­ line are used. In the case of acylation of the active principle with polymers bearing activated carboxy groups, placed in ripetitive and contiguous manner on the polymeric backbone, as for instance in the case of polyacrylic acid, quantitative yields in the binding process of the active principle require stoichiometrics even of 1:3O as CDP-choline moles: equivalents of acid groups in the polymer. In fact, due to its steric hin­ drance, a CDP-choline molecule bound to the polymeric matrix, tends to prevent new drug mulecules from bind­ ing to the contiguous activated acid sites. Once com­ pleted the CDP-choline binding reaction, the activating groups present in excess may be removed either by H₂O treatment or by treatment with ethanol, forming ethyl esters. In the former case, a polymer which at physio­ logical pH has a mainly ionic character is obtained, while in the latter case the polymeric matrix turns out to be considerably more hydrophobic. e) Reaction kinetics: the acylation reaction runs more rapidly in the presence of catalysts such as pyridine or dimethylaminopyridine. The high temperatures give shorter reaction times but above 7O°C the hydrolysis reaction of CDP-choline at the level of the pyropho­ sphoric bridge occurs, which is an undesired side-ef­ fect; optimal temperatures for a fast acylation process with high yields range from 4O to 6O°C. Generally, the acylation reaction of CDP-choline takes place in high yields (> 9O°C) and, according to the nature of the acylating reagent and to the reaction times, may invol­ ve one, two or all three molecular sites which may be acylated. For instance, using polymeric matrices with activated carboxy groups, such as imidazolides, only the acylation of the NH₂ moiety in 4 on the cytosine nucleus is obtained after reaction times from 48 to 96 hours. On the contrary, using as acylating reagents the imidazolides of monomeric polymerizable units, such as acrylic and methacrylic acids, in the same reaction times even the hydroxy moieties of the ribose component are acylated. f) Polymerization: this synthetic step is required when the formation of the polymeric skeleton is a step sub­ sequent to that of CDP-choline acylation. This is gene­ rally carried out with unsaturated acids, such as acry­ lic or methacrylic acid, whose derivatives with the active principle may be then easily polymerized in the presence of catalysts such as ammonium persulfate in aqueous medium, or 2,2′-azobis(isobutyrronitrile) in organic medium. The acylated derivative of CDP-choline is first purified from the reaction mixture by pre­ cipitation with about 3 volumes of a slightly polar organic solvent such as ethyl acetate and tetrahydrofu­ ran. Since the polymerization of said highly hindering acylated CDP-choline derivatives may be prevented by steric factors, it is convenient to add polymerizable units acting as spacing groups, thereby forming a copo­ lymer. In the case of mono- or diacylated CDP-choline derivatives with acrylic acid, good spacing groups may be for instance acrylic acid itself, acrylamide or methacrylic acid. The polymerization reaction in aqueous medium may be carried out, for example, using mono- and di-acryloyl-­ CDP-choline with acrylic acid in a molar ratio of 1:6. The reaction, carried out at room temperature under nitrogen in the presence of ammonium persulfate as a catalyst, is completed in about 12 hours. In this case, a cross-linked macromolecule having molecular weight > 5 × 1O³ and < 15 × 1O³ is obtained. g) Purification of the macromulecular CDP-choline deriva­ tive: the more effective purification system which may be used is the ultrafiltration, using membranes having appropriate "cut-off". After removal under vacuum of the organic solvents possibly present, the polymer aqueous solution is ultra-filtered, allowing to recover the macromolecular fraction alone, which may be there­ after lyophilized. This kind of process may be easily carried out at production level, using standard, indu­ strial ultrafiltration units. Alternatively, the deri­ vative object of the invention may be precipitated from the aqueous solutions by addition of hydrophilic orga­ nic solvents, such as tetrahydrofuran, acetone or buta­ nol. The previously described synthetic methods allow the preparation of a wide range of polymeric CDP-choline derivatives. Those having high molecular weight, which may be represented by the following formula: wherein n is an integer from 5 to 3O and X and X′ may represent one of the following groups: are preferably prepared using high molecular weight poly­ meric matrices having linear or cross-linked structure, whose carboxy groups, compatibly with the steric hindran­ ces, are linked to the CDP-choline, generally only through one of the three possible acylation sites, preferably the amine moiety in 4 on the cytosine nucleus. Using hydrosoluble polymeric matrices the CDP-cho­ line derivatives remain soluble, giving viscous solutions. Increases in the cross-linking degree of the polymeric matrix involve a lower solubility and products with a lower amount of CDP-choline for unitary amounts of polymers. Low molecular weight ( < 2O × 1O³) polymeric CDP-­ choline derivatives of the cross-linked type, which may be schematically represented by the following formula wherein n is an integer from 1 to 1O the -NH-R-O- bridge has the following formula and X and X⁻ may represent one of the following groups are preferably prepared by copolymerization of mono- or di-acylated CDP-choline derivatives with unsaturated acids or other spacing monomeric units. The polymeric derivatives of CDP-choline in lyophi­ lized form are white amorphous, indefinitely stable solids. Analogous stability is shown when the products are preserved in aqueous solutions. As a whole, the methods hereinabove described, for their easiness and low cost, may be easily applied at the industrial level. The compounds of the invention, due to their biolo­ gical properties and their behaviour as pro-drugs of the known parent molecule, CDP-choline, may be conveniently used as active principles of pharmaceutical compositions suited for the oral or parenteral administrations, to be used for substantially the same indications of CDP-choli­ ne. Examples of pathologies which may be usefully trea­ ted with the compositions of the invention include: - sclerotic vasculopathies mainly interesting the cerebro­ vascular district; - short- and long-term treatment of cerebrovascular ictuses; - short- and long-term treatment of cerebral ictus conse­ quences; - therapy of the parkinsonian syndrome, in particular in the atherosclerotic form; - antidepressive treatment; - treatment of traumatic cerebral ; - prevention and therapy of the ialine membrane disease (IRDS); - therapy of acute and chronic hepatitis (viral hepatitis etc.); - therapy and prevention of the fat liver in alcoholics; - coadjuvant therapy in hepatic cirrhosis; - degenerative phenomena due to aging. The posology of the derivatives of the invention will be determined by their CDP-choline content, and will be so as to allow a daily administration of 1OO-1,OOO mg of CDP-choline. The compositions object of the invention will be formulated according to conventional methods, using con­ ventional excipients or carriers. The following Examples, illustrating the prepara­ tion and the biological experimentation of a series of polymeric derivatives of CDP-choline, concern only some of the numerous possibilities which may be proposed and do not limit therefore the scope of the invention. EXAMPLE 1 5O Grams of CDP-choline (O.1 mole) were neutralized with O.1 mole of tetrahexylammonium hydroxide. After remo­ tion of water by freeze-drying, the salt was dissolved in 2.5 l of anhydrous dimethylformamide (DMF). 3 Equivalents of polyacrylic acid (equivalent wei­ ght of the monomeric unit: 7O), Mw 2.5 × 1O⁵, dissolved in 2.5 l of anhydrous DMF, were activated as imidazolide by treatment with 3 moles of carbonyl diimidazole. The reac­ tion was carried out at room temperature, and it was com­ plete within about 3O min., as evidenced by the end of CO₂ evolution in the solution. The binding reaction of CDP-choline to the polyme­ ric matrix was effected by admixing the CDP-choline tetra­ hexylammonium salt solution with polyacrylic acid imidazo­ lide, in the presence of 4-N-dimethylamino-pyridine (DMAP) in catalytic amounts (∼ 1 g). The reaction, occurring in homogeneous phase, was left under stirring at 4O°C for 96 hours. After recovering of the solvent by evaporation under vacuum, the dried residue was taken up into 5 l of water and dialyzed against water, using a dialysis membra­ ne having a cut-off of 2O,OOO. The low molecular weight material was thus separat­ ed and the imidazole groups still present on the carboxy residues were removed. The dialyzed, which could not cross the membrane due to its high molecular weight, was thereafter freeze-­ dried. Binding of CDP-choline to the polymeric matrix occurred in 9O% yields. The obtained product is a white amorphous not hygroscopic solid, which is indefinitely stable at room temperature and, dissolved in water, yields clear and viscous solutions. The so obtained CDP-choline macromolecular derivative has a molecular weight which may be evaluated in 3 × 1O⁵ by means of gel-filtration measu­ rements on Sephadex G-2OO and ultrafiltration on Amicon XM-3OO membranes with rejection of molecular species > 3 × 1O⁵ CDP-choline macromolecular derivative in aqueous solution shows a maximum at 297 nm, which is typical of CDP-choline N-acylated derivatives, thus evidencing that the active principle, is, under these reaction conditions, bonded to the polymeric matrix by an amide bond at the level of the amino group at -4 on the citosine nucleus. ¹H-NMR spectrum in D₂O shows, in addition to the broad signals of the polymeric matrix in the interval δ 1.1-2.5 (-CH₂- H ), the CDP-choline signals at δ 7.4 (H-5), 8.4 (H-6), 6.O (H-1′), 4.4-4.2 (H-2′,3′,4′,5′ and C H ₂ -O-P choline), 3.7 (CH₂-N choline), 3.2 (C H ₃ choline), which loose their multiplicity and broaden, being bonded to the polymeric matrix. Particularly, the ¹H-NMR data confirm that CDP-choline binding to the polymeric matrix occurs at level of the amino group in 4 of the cytosine nucleus; in fact, the signal of the cytosine proton in 5 falls at lower fields with respect to CDP-choline, analogously to what observed for the other N-acylated derivatives. On the contrary, the protons in 2′ and 3′ of ribose resonate at the same fields as in CDP-choline, confirming that the sugar hydroxy groups are not esterified. EXAMPLE 2 The procedure of Example 1 was repeated, but the purification process of macromolecular CDP-choline deriva­ tive from the DMF solution was carried out by precipita­ tion with 3 volumes of ethyl acetate. The solid material, washed with O.5 liters of ethyl acetate, was dissolved in 1 l of H₂O and left under stirring for 24 hours at 4O°C, in order to remove the imidazole groups possibly present on the carboxy functions. The solution, concentrated on an ultra-filtration device having membranes with cut-off > 1OO,OOO was free­ ze-dried. The product obtained presents the same characte­ ristics of the product obtained in Example 1. EXAMPLE 3 The procedure of Example 3 was repeated but when the binding reaction was over, O.5 l of ethanol were added to the reaction mixture, which was kept for 24 hours at room temperature under stirring. In this way the carboxy residues still activated as imidazolides form ester bonds with the alcohol molecules. After removal of the solvent under vacuum, the dry residue was dyalized against water, using a membrane having a cut-off of about 5O,OOO. In this way, the low molecular weight components were separated, whereas the CDP-choline derivative remained. The obtained product shows spectroscopical charac­ teristics similar to that of Example 1, with the exclusion of the ¹H-NMR signals due to the ethyl residues esterify­ ing a part of the acid moieties of the polymeric matrix. EXAMPLE 4 1OO Grams of CDP-choline (O.2 mole) were dissolved in 14O ml of a 4O% tetrahexylammonium solution and free­ ze-dried. The dry CDP-choline tetrahexylammonium salt was then dissolved in 5 l of anhydrous DMF. 1.8 Moles of acry­ lic acid, dissolved in 2 l of anhydrous DMF, were then reacted with 2.5 moles of carbonyldiimidazole up to ceased CO₂ evolution. The CDP-choline tetrahexylammonium salt and 1 g of DMAP in DMF were added to the acrylic acid imidazo­ lide solution, the reaction was kept at room temperature under stirring for 48 hours. The reaction mixture, analyz­ ed on silica thin layer, using as eluent methanol:acetic acid:H₂O (5O:15:35 by volume), showed the presence of CDP-choline di-acylated products, with minor amounts of mono- and tri-acylated species. After evaporation of the mixture up to 1/4 of the volume, the CDP-choline acylated species were recovered by precipitation with 3 volumes of ethyl acetate. The product was dried under vacuum in order to remove solvent traces; the yield in acylated derivatives of CDP-choline was about 90%. 1OO Grams of the CDP-choline acylated products were dissolved in 6 l of a 1OO mM ammonium formiate buffer, adding O.5 kg of polyacrylic acid and 6 ml of tetramethyl­ ethylendiamine (TEMED) as a catalyst for the polymeriza­ tion reaction; the so prepared reaction was kept under nitrogen flow for 3O′. The polymerization was carried out under protected atmosphere adding 1O mmoles of ammonium persulfate; the reaction at 3O°C was completed in about 24 hours. The polymerization product was purified by ultra-­ filtration, using a membrane having a cut-off higher than 5 × 1O³. The spectroscopical characteristics of the pro­ duct were analogous to those described in Example 1, the molecular weight, evaluated by membrane filtration, was ranging from 5 × 1O³ and 2O × 1O³. The yield in the poly­ merization process was higher than 9O%. EXAMPLE 5 1OO Mg of (5-³H; Met-¹⁴C)CDP-choline (1 mCi of ³H and O.5 mCi of ¹⁴C) tetrahexylammonium salt, dissolved in 8 ml of anhydrous DMF, were reacted with 4 moles of poly­ acrylic acid imidazolide (Mw 2.5 × 1O⁵), in the presence of 5 mg of DMAP as a catalyst. The reaction was carried out under the conditions of Example 1 and the labelled macromolecular CDP-choline derivative was purified by ultrafiltration on membranes having cut-off of 5 × 1O⁴. 4O Rats (mean body weight 2OO g) were orally admi­ nistered by gastric tube with a dose of the labelled pro­ duct corresponding to 2 mg of active principle (2O mCi of ³H and 1O mCi of ¹⁴C). The animals (1O per group) were sacrificed at 2, 8, 24 and 48 hours. The plasma, stomach, small intestine, large bowel, the gastric and intestinal content, liver, kidneys, feces and urine were removed from the animals and rapidly freezed. The radioactivity level was determined on the biological specimens. The pharmaco-­ kinetic pattern showed that CDP-choline was gradually released from the polymeric matrix, essentially at level of the small intestine, where the drug was effectively absorbed. After 8 hours, 8O% of the radioactivity in the small intestine content was due to CDP-choline still bound to the polymeric matrix. The distribution pattern of the radioactivity in the organism was comparable to what noti­ ced in the case of administration of doubly-labelled CDP-­ choline by the oral route, with the difference that in the case of the macromolecular CDP-choline derivative the radioactivity levels were more prolonged in time. The faecal and urinary excretion of radioactivity were extre­ mely poor.

Claims: 1. Macromolecular CDP-choline derivatives wherein CDP-choline is covalently bonded to a polymeric matrix containing carboxy groups, by means of amide bonds involv­ ing said carboxy groups and the NH₂ group in 4 on the aromatic nucleus of the CDP-choline and/or by means of ester bonds between said carboxy groups and the OH groups in 2′ and 3′ of ribose. 2. Derivatives according to claim 1, wherein the poly­ meric matrix is selected from the group consisting of polyacrylic acids, polymethacrylic, polymaleic, polyamino­ acids, optionally copolymerized acids with polyacrylates, polymethacrylates and polyacrylamides. 3. Derivatives according to claim 1 or 2, wherein CDP-choline is bound to the polycarboxylic polymeric ma­ trix through an amide bond between the carboxy groups of said polymeric matrix and the NH₂ group in 4 of CDP-cho­ line. 4. Derivatives according to claim 1 or 2, wherein CDP-choline is bound to a cross-linked polymeric matrix through amide bonds between the carboxy groups of the polymeric matrix and the NH₂ group in 4 of CDP-choline and through ester bonds between said carboxy groups and one of the OH groups in position 2′ or 3′ of ribose. 5. Derivatives according to any one of the claims from 1 to 5, wherein the carboxy groups of the polymeric matrix not involved in covalent bonds with CDP-choline, are este­ rified with a lower alcohol. 6. A process for the preparation of derivatives of claim 1, characterized in that a CDP-choline salt with a lipophilic cation is reacted with polymers containing activated carboxy groups, in anhydrous organic solvents and that the reaction mixture is treated with water or lower alcohols. 7. A process according to claim 6, characterized in that a long-chain quaternary ammonium group, preferably tetrahexylammonium, is used as lipophilic cation, and that the carboxy groups are activated as chlorides, anhydrides or imidazolides. 8. A process for the preparation of the derivatives of claim 4, characterized in that unsaturated polymerizable acids are copolymerized with lipophilic salts of CDP-cho­ line derivatives N- and/or O-acylated, in anhydrous orga­ nic solvents. 9. A process according to claim 8, characterized in that the unsaturated polymerizable acids are selected from the group consisting of acrylic, methacrylic, maleic acids and that the polymerization is carried out by radicalic catalysis. 1O. Pharmaceutical compositions suited to the oral or parenteral administrations containing as active principles the derivatives of claims 1-5 in admixture with conventio­ nal carriers and excipients. Claims for the following Contracting States : AT, ES, GR 1. A process for the preparation of macromolecular CDP-choline derivatives wherein CDP-choline is covalently bound to a polymeric matrix containing carboxy groups by means of amide bonds involving said carboxy groups with the NH₂ group in 4 on the aromatic nucleus of the CDP-cho­ line and/or by means of ester bonds between said carboxy groups and the OH groups in 2′ and 3′ of ribose, characte­ rized in that CDP-choline salt with a lipophilic cation is reacted with polymers containing activated carboxy groups, in anhydrous organic solvents and that the reaction mixtu­ re is treated with water or lower alcohols. 2. A process according to claim 1, characterized in that as lipophilic cation a long-chain quaternary ammonium group is used, preferably tetrahexylammonium and that the carboxy groups are activated as chlorides, anhydrides or imidazolides. 3. A process for the preparation of macromolecular CDP-choline derivatives wherein CDP-choline is bound to a cross-linked polymeric matrix through amide bonds between the carboxy groups of the polymeric matrix and the amine group in 4 of CDP-choline and through ester bonds between said carboxy groups and one of the OH groups in position 2′ or 3′ of ribose, characterized in that polymerizable unsaturated acids are copolymerized with lipophilic salts of CDP-choline derivatives N- and/or O-acylated, in anhy­ drous organic solvents. 4. A process according to claim 3, characterized in that the unsaturated polymerizable acids are selected from the group consisting of acrylic, methacrylic, maleic acid and that the polymerization is carried out by radicalic catalysis.

Inventors: ZAPPIA, VINCENZO, CYANAMID ITALIA S.P.A.
Applicants: DE ROSA, MARIO, ZAPPIA, VINCENZO
Application year: 1986
Main classification: A61K47
IPC codes: A61P25, A61K31, A61K47, C07H19, A61P9, A61P1, C08L101